BioRestorative Therapies, Inc. BRTX
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -10.34%
- 1 year
- -5.50%
- Market cap
- 1.45M
- Revenue (ttm)
- 377.00K
- EPS (ttm)
- -21.40
- Shares out
- 6.92M
- Forward P/E
- -0.90
- YTD return
- -10.34%
- 1-year return
- -5.50%
- Volume
- 29.75K
- Avg volume
- 29.59K
- Open
- 1.32
- Previous close
- 1.31
- Day's range
- 1.05 – 1.36
- 52-week range
- 1.04 – 24.40
- Price target
- 13.00 (+1139.3%)
Key statistics
- 50-day average
- 1.54
- 200-day average
- 1.53
- Enterprise value
- -2.31M
- Price / sales
- 28.27
- Price / book
- 1.07
- Revenue growth
- 660.90%
- Free cash flow
- -2.40M
- Total cash
- 13.09M
- Total debt
- 42.41K
- Return on equity
- -17.12%
- Short % of float
- 1.18%
Fundamental scorecard
10 of 25 checks passed on BRTX’s reported financials
10of 25 checks passed
- Value 2 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Mar 31, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.35 | -0.13 | +0.22 | +62.86% |
| Aug 13, 2024 | Jun 1, 2024 | -0.56 | -0.50 | +0.06 | +10.71% |
| Mar 29, 2024 | Dec 1, 2023 | -0.65 | -0.57 | +0.08 | +12.31% |
| Nov 13, 2023 | Sep 1, 2023 | -0.68 | -0.64 | +0.04 | +5.88% |
| Aug 11, 2023 | Jun 1, 2023 | -1.56 | -0.77 | +0.79 | +50.64% |
| Mar 24, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 14, 2024 | Roth MKM | main | Buy | Buy |
| Jun 12, 2024 | Roth MKM | main | Buy | Buy |
| Aug 14, 2023 | Roth MKM | reit | Buy | Buy |
| Dec 7, 2022 | Roth Capital | init | — | Buy |
| Sep 28, 2022 | Maxim Group | init | — | Buy |
| Dec 1, 2021 | Roth Capital | init | — | Buy |
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs relate to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is based in Melville, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- biorestorative.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on BRTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALSTODT LANCE | Chief Executive Officer | Purchase | Sep 14, 2023 | 189,505 |
| BROADRICK DALE | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 27, 2024 | 923,905 |
| SILVA FRANCISCO | Officer and Director | Purchase | Apr 8, 2024 | 167,895 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 6.39% | 55,706 | 85.79K | Sep 29, 2024 |
| Stonex Group Inc. | 5.74% | 50,100 | 77.15K | Sep 29, 2024 |
| Wealth Alliance | 4.59% | 40,000 | 61.60K | Sep 29, 2024 |
| Vanguard Group Inc | 2.35% | 20,472 | 31.53K | Sep 29, 2024 |
| State Street Corporation | 2.35% | 20,459 | 31.51K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 2.29% | 20,000 | 30.80K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 3.39% | 29,538 | 45.49K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 2.35% | 20,472 | 31.53K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 1.55% | 13,485 | 20.77K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.80% | 6,987 | 10.76K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.44% | 3,862 | 5.95K | Oct 30, 2024 |
